Victory Capital Management Inc. Purchases 82,691 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Key Points

• Victory Capital Management Inc. increased its stake in Amicus Therapeutics by **47.4%**, acquiring an additional **82,691 shares** during the 1st quarter, bringing its total holdings to **257,088 shares** valued at approximately **$2.1 million**.
• Multiple hedge funds have adjusted their positions in Amicus, with **Wellington Management Group LLP** increasing its holdings by **18.8%** and **Orbimed Advisors LLC** raising its stake by an impressive **300.7%** in the last quarter.
• Wall Street analysts have mixed sentiments about the stock, with ratings varying from a **"buy"** from UBS Group to a **"hold"** rating from Wall Street Zen, indicating a consensus average rating of **"Moderate Buy."**

Victory Capital Management Inc. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 47.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 257,088 shares of the biopharmaceutical company's stock after acquiring an additional 82,691 shares during the period. Victory Capital Management Inc. owned approximately 0.08% of Amicus Therapeutics worth $2,098,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in FOLD. Virtus Fund Advisers LLC bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $29,000. Covestor Ltd grew its position in Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Amicus Therapeutics during the 4th quarter worth approximately $59,000. GAMMA Investing LLC grew its position in Amicus Therapeutics by 1,610.8% during the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,007 shares during the last quarter. Finally, Thrivent Financial for Lutherans bought a new stake in Amicus Therapeutics during the 4th quarter worth approximately $104,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group decreased their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, UBS Group increased their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Amicus Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Trading Up 5.3%

Amicus Therapeutics stock traded up $0.32 during mid-day trading on Friday, hitting $6.31. 2,220,918 shares of the company's stock were exchanged, compared to its average volume of 3,817,707. The company's 50 day simple moving average is $6.05 and its 200-day simple moving average is $7.47. The firm has a market capitalization of $1.94 billion, a P/E ratio of -70.05 and a beta of 0.51. The company has a quick ratio of 2.47, a current ratio of 3.34 and a debt-to-equity ratio of 2.02. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.